Testimonios de nuestros clientes
Su pedido
€ 0.00 (0 artículos)
Search:
Perform search
Lista de categorías

Genérico Loxapine - Loxitane

Nuevo
Búsqueda por letra:ABCDEFGHIJKLMNOPQRSTUVWXYZ
Loxitane
El Loxitane Genérico es un medicamento antipsicótico. Se utiliza para tratar la esquizofrenia.
€ 0.72
País, idioma y moneda


Garantíade devolución
Comprasegura

Nuestra página de facturación está certificada por:

Secure shopping certificates

Special Offer!

  • FDA Rejects Loxapine for Approval - Medscape

    RTT NewsFDA Rejects Loxapine for ApprovalMedscapeMay 5, 2012 — The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) saying that the new drug application for loxapine inhalation powder (Adasuve, Alexza Pharmaceuticals, Inc) is not ready for approval in its current .

  • FDA again rejects Alexza's Adasuve, citing manufacturing deficiencies - The Pharma Letter

    FDA again rejects Alexza's Adasuve, citing manufacturing deficienciesThe Pharma LetterLoxapine already is approved in a capsule form for long-term treatment of schizophrenia, but Alexza is seeking approval for an inhaled form that would be administered for acute agitation associated with schizophrenia or bipolar I disorder in adults.

  • Common antipsychotic drugs - GazetteNET

    Common antipsychotic drugsGazetteNETBy THE DAILY HAMPSHIRE GAZETTE Abilify (aripiprazole), Clozaril (clozapine), Fanapt (iloperidone), fluphenazine (generic only), Geodon (ziprasidone), Haldol (haloperidol), Invega (paliperidone), Loxitane (loxapine), Moban (molindone), .

  • Benzinga's Microcap Movers for Friday May 4, 2012 - Benzinga

    Benzinga's Microcap Movers for Friday May 4, 2012BenzingaAlexza Pharmaceuticals announced Thursday that it had received a Complete Response Letter from the US Food and Drug Administration regarding its New Drug Application for ADASUVE (loxapine) inhalation powder, 5 mg and 10 mg.

  • Biotech Industry Hotbed of Merger & Acquisition Speculation - MarketWatch (press release)

    Biotech Industry Hotbed of Merger & Acquisition SpeculationMarketWatch (press release)The company recently received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its New Drug Application for ADASUVE (loxapine) inhalation powder.

    Copyright © www.cajera.com is an affiliate marketing website. Todos los derechos reservados. | Tools fuer Webmaster.